NeOnc Technologies Secures $16 Million PIPE Investment to Advance CNS Cancer Therapies
Key Insights
NeOnc Technologies secured up to $16 million in PIPE funding led by Cinctive Capital Management (search)'s $10 million investment to advance central nervous system cancer treatments.
The company's NEO100 and NEO212 therapeutics are currently in Phase II clinical trials with FDA Fast-Track status for treating malignant gliomas.
NeOnc's proprietary NEO drug development platform addresses blood-brain barrier challenges with patent protections extending to 2038.
NeOnc Technologies Holdings (search), Inc. (Nasdaq: NTHI), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, announced a strategic private investment in public equity (PIPE) transaction expected to generate up to approximately $16 million in gross proceeds. The funding round is led by a $10 million investment from Cinctive Capital Management (search) LP, a multi-strategy investment firm focused on biotechnology and therapeutics.
The securities purchase agreement involves the sale of up to 2,222,222 shares of common stock and five-year warrants to purchase up to 2,222,222 shares at a per share exercise price of $9.00, with a combined purchase price of $7.20. NeOnc plans to use the net proceeds for debt repayment, working capital, and general corporate purposes.
Institutional Validation of CNS Cancer Platform
The investment represents significant institutional endorsement of NeOnc's technological approach to overcoming blood-brain barrier challenges in CNS therapeutics. Amir F. Heshmatpour, Executive Chairman, President & CEO of NeOnc Technologies, stated: "This strategic investment from a firm of Cinctive Capital's caliber validates our technological approach and the potential of our clinical assets. Rich's track record in identifying high-value opportunities is well recognized. We believe this capital will be instrumental as we accelerate our clinical trials and continue to develop therapies designed to bypass the blood-brain barrier."
Rich Schimel, Co-Founder and Co-Chief Investment Officer of Cinctive Capital Management (search) LP, commented: "We see tremendous potential in NeOnc's proprietary delivery platforms. Our firm seeks opportunities in small-to-mid-cap biotech companies that demonstrate true innovation, and NeOnc fits this profile well. Cinctive's commitment to recognizing value in unique opportunities is underscored by this transaction with NeOnc, following a similarly structured recent deal with Lifezone Metals. We are pleased to support their mission to improve outcomes for patients with CNS disease."
Advanced Clinical Pipeline with FDA Recognition
NeOnc's NEO drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. The company's proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas.
The company's lead therapeutics, NEO100 and NEO212, are currently advancing through Phase II human clinical trials under FDA Fast-Track and Investigational New Drug (IND) status. This regulatory designation reflects the FDA's recognition of the potential significance of these treatments for addressing unmet medical needs in CNS cancers.
Comprehensive Intellectual Property Portfolio
NeOnc has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California, consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family. The intellectual property covers multiple uses, including oncological and neurological conditions, providing broad commercial potential for the company's therapeutic platform.
The clinical-stage life sciences company focuses specifically on the development and commercialization of central nervous system therapeutics designed to address the persistent challenges in overcoming the blood-brain barrier, a critical obstacle in delivering effective treatments to brain cancer patients.